Team

Team 2018-10-11T09:39:00+00:00

The Company has a very experienced senior leadership team consisting of Dr Joe Anderson, Chief Executive Officer, Jonathan Peacock, Chairman and Professor Sir Chris Evans, Deputy Chairman. Each provides the Company with highly complementary skills covering a wide range of healthcare and life science disciplines from academic science, through clinical and commercial strategy, company operations to venture capital, M&A and corporate finance. Collectively, they have founded, financed, developed and operated multiple life science companies, both large and small, and have contributed to the creation of substantial value for shareholders.  In addition, Arix Bioscience is in the process of recruiting additional personnel to enable the Group to further implement its business strategy both in London and New York.

The team

Board of Directors

Jonathan Peacock

Jonathan Peacock

Executive Chairman

Jonathan has 35 years’ global experience in operations, strategy and business development. He is the former CFO of Amgen Inc. based in California, USA and prior to that was the CFO of the Pharmaceuticals Division of Novartis AG, based in Switzerland with global responsibilities including business development and strategy.

During Jonathan’s tenure as CFO of Amgen, Amgen Inc.’s share price increased by approximately 125%. Novartis Pharma AG’s operating profit increased over 40% during his tenure as CFO of that company. He has raised over $20bn in new capital and has been engaged throughout his career in business development and mergers and acquisitions on both the buy-side and sell-side globally. Jonathan was the CEO of NASDAQ-listed Bellerophon Therapeutics until 11 November 2016 and is currently the Chairman; he was formally a non-executive director of Kite Pharma from 2014 to 2017 where he sat on the Board’s Transaction Committee for the successful acquisition of Kite by Gilead Sciences for $11.9bn in August 2017. He brings to the Company hands-on experience in managing large and small biopharma companies and a unique perspective on the factors driving successful partnerships or investments by bigger biopharma companies

Dr Joe Anderson

Dr Joe Anderson, PhD

Chief Investment Officer

Joe has over 25 years’ experience in the life sciences industry, with a successful track record of generating investment returns. He was formerly a Partner at Abingworth LLP for 12 years, where he led venture-capital style investments in public companies. He has founded and managed public equities funds and been a director of Algeta (acquired by Bayer Ag for $2.9bn), Amarin plc, Cytos (merged with Kuros), Epigenomics Ag, and is currently a director of Autolus Ltd.

He began his career at the Ciba (now Novartis) Foundation, before joining the The Wellcome Trust in 1990 where he became head of the strategy team. He then moved to the City of London as a pharmaceuticals analyst at Dresdner Kleinwort Benson, before being appointed as Head of Global Healthcare and Portfolio Manager at First State Investments, Commonwealth Bank of Australia, in London. Joe has a PhD in Biochemistry and extensive board level experience of building successful life sciences companies.

Sir Chris Evans

Sir Chris Evans

Deputy Chairman

Sir Chris is a renowned scientist and highly successful entrepreneur with numerous prestigious awards and medals for his work over the last 30 years. He is the founder and Chairman of Excalibur Group and has created 11 successful academic spin-outs and founded notable companies such as Chiroscience, Celsis, BioVex, ReNeuron, Vectura and Merlin Biosciences Ltd. He directed the raising of approximately $450 million for Merlin Biosciences Funds and $2.6 billion from disposals including the sale of BioVex Group, Inc to Amgen Inc and Piramed Limited to Roche Group.

Through Merlin Ventures Limited, he co-founded and advised Biotech Growth Trust plc and Arakis Limited, one of the companies developed by Sir Chris which was sold to Sosei Co. Ltd for $187 million. Sir Chris has founded multiple listed companies with a collective market cap (as at the end of April 2016) of around $2.4 billion. Appointed OBE in 1995 for services to medical bioscience, he was then knighted in 2001 for services to bioscience and enterprise.

James Rawlingson

James Rawlingson

Chief Financial Officer

James has substantial experience at board and senior management level gained over 20 years of involvement in financial services and UK public companies. James’ former role was Group CFO of Charles Stanley plc, a leading wealth manager with over £20 billion of funds under management and administration. Previously, James was Group CFO for Coutts Bank, where he was responsible for the global finance function and held a key role in setting strategy. Before this James spent two years at UBS Wealth Management based in Zurich after promotion from his role as CFO of UBS Wealth UK.

Franz Humer

Franz Humer

Senior Independent Director

Franz has over 25 years of experience as an executive director of global blue chip companies. He was the managing director of Glaxo Pharmaceuticals UK Limited, was elected to the board of Glaxo Holdings plc, and became the chief operating director for its worldwide operations, in 1992. In 1995, he joined Hoffman-La Roche as a member of its Board and the head of its pharmaceuticals division, progressing to become Chairman and CEO in 2001, and between 2008 and 2014 the Chaiman of Roche Holding Limited.

Franz joined the board of Diageo in 2005, became Chairman in 2008 andresigned in 2016. He is also Chairman of PCI Services; a non-executive director of Citigroup, Inc., Bial Pharmaceuticals of Portugal and Allogene Therapeutics, Inc.; and an Advisor to Temasek Holdings. From 2015 to 2017, he was a non-executive director of Kite Pharma, until the company’s acquisition by Gilead Sciences for $11.9bn in August 2017. Dr Humer has a PhD in law from the University of Innsbruck and an MBA from INSEAD in Fontainbleau, France. He is the Chairman of the Board of the International Centre for Missing and Exploited Children. Franz has been awarded the Singapore Public Service Star and Austria’s ‘Grosses goldenes Ehrenzeichen mit dem Stern für Verdienste’.

Professor Trevor Jones

Professor Trevor Jones

Independent Non-Executive Director

Trevor has led a distinguished career in the pharmaceutical and biotech industry as well as in academia. He was Group R&D director at The Wellcome Foundation, responsible for the development of AZT, Zovirax, Lamictal, Malarone and other medicines. Following this, he was a director of Allergan Inc (USA) for 10 years until 2015. Trevor was formerly Director General of the Association of the British Pharmaceutical Industry (ABPI), served for 12 years as a member of the UK Government Regulatory Agency Medicines Commission and acted as chairman of the UK Government Advisory Group on Genetics Research. He is a visiting professor at King’s College, London and holds honorary degrees and gold medals from six universities. In 2004, he was appointed to the World Health Organisation Commission on Intellectual Property Rights, Innovation and Public Health. In 2003, Trevor was appointed CBE for services to the pharmaceutical industry.

Arthur Pappas

Independent Non-Executive Director

Arthur Pappas has over 30 years of experience as a pharmaceutical and biotechnology industry executive, and venture capital investor in life science companies. He is the founder and managing partner of Pappas Capital, a leading US venture firm. Prior to founding Pappas Capital in 1994, Art held senior level leadership positions at several multinational pharmaceutical companies for which he was responsible for the development, licensing and launch of a number of global products. He was an executive member of the board of directors of Glaxo Holdings plc (NYSE: GLX, now GSK), and served as Glaxo’s chief executive responsible for international operations including research, development and manufacturing. Prior to Glaxo, Art was Vice President of Commercial Operations for Abbott International, and he held various executive and general management positions with Merrell Dow Pharmaceuticals and the Dow Chemical Company, in the United States and internationally. He previously served as Chairman and founding CEO of CoLucid Pharmaceuticals (NASDAQ: CLCD) (acquired by Eli Lilly in 2017), and on the boards of Afferent Pharmaceuticals (acquired by Merck in 2016), Chimerix (NASDAQ: CMRX), Quintiles Transnational Corp. (now part of IQVIA) (NYSE: IQV), TYRX (acquired by Medtronic in 2013), Syntonix Pharmaceuticals (acquired by Biogen IDEC in 2007), LEAD Therapeutics (acquired by BioMarin in 2010), CardioDx, and Embrex (NASDAQ: EMBX) (acquired by Pfizer in 2006). He also served as a board observer for Plexxikon, which was sold to Daiichi Sankyo in 2011.

Art is a member of the Board of Directors of the North Carolina Biotechnology Center, where he was a past chair, and the Medical University of South Carolina Foundation for Research Development. He is a member of the Board of Trustees of The Wistar Institute (a National Cancer Institute center), the Board of Advisors of the Duke Cancer Institute, and the Advisory Board of the BioExec Institute. He is also a member of the CEO Roundtable on Cancer and BayHelix, an organization of global life science community leaders. He previously served on the Board of Directors of the National Venture Capital Association. Art is a decorated Vietnam veteran, having served as an officer in the US Army 101st Airborne Division and 2nd PSYOP Airborne Group JFK Special Warfare Center.

Giles Kerr

Independent Non-Executive Director

Giles has 36 years’ experience in finance across a broad range of industrial sectors with a particular focus on life sciences. He is currently CFO of Oxford University and during his time at Oxford has established a successful investment office with £2.5bn under management and a £650m early-stage investment fund. Through his role on the board of Oxford University’s technology transfer company, Oxford University Innovation Ltd., he has gained considerable experience of establishing and growing technology based companies. Prior to joining Oxford University he was CFO of Amersham plc and during his time at Amersham the share price increased seven fold. Giles has extensive experience as chairman and as a member of UK and US listed company audit committees and is currently Chairman of the audit committees of Senior plc, Paypoint plc and a member of the audit committees of BTG plc and Adaptimune Therapeutics plc. Prior to joining Amersham plc he was an audit partner with Arthur Anderson & Co.

Meghan FitzGerald

Meghan FitzGerald

Independent Non-Executive Director

Meghan has broad experience in the US healthcare industry, with a strong emphasis on operations, health policy and business development. She is a Partner at L1 Health, with a focus on investing in healthcare services. She is also an Associate Professor of Strategy and Health Policy at Columbia University. Prior to joining L1 Health, Meghan served as Executive Vice President of Strategy and Health Policy at Cardinal Health, the global integrated healthcare services and products provider, and before then was President of Cardinal’s Specialty Solutions division. She holds a DrPh in Healthcare Policy from New York Medical College, a BSN in Nursing from Fairfield University, and a Master of Public Health from Columbia University.

Business Development Team

Edward Rayner

Edward Rayner

Before joining Arix Bioscience at its inception, Ed spent 18 years as an equity analyst and Portfolio Manager in Europe and Australia. From 2004 to 2014, he was Head of Research at Alliance Bernstein and then a senior portfolio manager at AMP Capital, a leading Australian investment house with over A$130bn in funds under management, both in Sydney, Australia. At AMP Capital, he managed the growth equity portfolios and launched a small companies fund. As part of his responsibilities he focused on the Healthcare sector.

Prior to his move to Australia, Ed analysed European equities at UBS Asset Management and JP Morgan Investment Management. He gained an MA in Chemistry and MSc in Management at the University of Oxford and is a Chartered Financial Analyst.

Jonathan Tobin

Jonathan Tobin

Jonathan specialises in biotechnology investments. He currently sits on the board of Artios Pharma. Prior to joining Arix Bioscience, Jonathan spent five years at Imperial Innovations, where he was a Principal in the Healthcare Ventures team. He was involved with the formation and investment in a number of early stage companies, including Inivata, Auspherix, Abingdon Health, Cell Medica, and Psioxus. Jonathan also worked at MRC Technology, sourcing and evaluating new small molecule and antibody drug discovery projects.

He has a first class degree in biology from the University of Oxford, a PhD in Molecular Medicine from UCL, carried out postdoctoral research at the Cancer Research UK London Research Institute (now Crick Institute), and published research in journals including PNAS, New England Journal of Medicine, and Nature Genetics. Jonathan also has an MBA with distinction from Imperial College, and is a Trustee of the Autism Research Trust.

Mark Chin

Mark Chin

Mark has over 10 years’ of experience in the life sciences industry.  He was previously a principal at Longitude Capital, where he focused on investments in both private and public biotechnology and medical technology companies.  Prior to Longitude, he was a consultant at the Boston Consulting Group, where he was responsible for strategy and corporate development projects for pharmaceutical and biotechnology companies.  Before BCG, Mark worked in corporate development at Gilead Sciences and market planning at Genentech.  Mark has an MBA from The Wharton School at the University of Pennsylvania, an MS in Biotechnology from the University of Pennsylvania, and a BS in Management Science from the University of California at San Diego.

Daniel O’Connell

Daniel O’Connell

Daniel has over 10 years’ of experience in healthcare. Daniel joined Arix Bioscience from OrbiMed Advisors, where he played key roles across investments in both biotherapeutics and medical devices. Investments he has supported include CardiAQ (acquired by Edwards), Civitas Therapeutics (acquired by Acorda), Relypsa (acquired by Galenica), Cynapsus (acquired by Sunovion), as well as other public and private companies.  Prior to OrbiMed, Daniel was the Associate Director of Cardiovascular Research at Arisaph Pharmaceuticals where he was responsible for pre-IND discovery and development for programs in lipid modulation. He received his MD and PhD in Biochemistry from Tufts University School of Medicine, and has undergraduate degrees in Mathematics and Chemistry from MIT.